Intersect ENT Inc (XENT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CEO:
Thomas A. West
Employees:
430
1555 ADAMS DRIVE, MENLO PARK, CA 94025
650-641-2100

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus. PROPel Mini, a releasing implant for patients undergoing frontal sinus surgery, is a steroid-release implant. VENSure Navigable and Stand-alone balloon is used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach.

Data derived from most recent annual or quarterly report
Market Cap 954.159 Million Shares Outstanding33.788 Million Avg 30-day Volume 683.958 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.85
Price to Revenue9.0862 Debt to Equity-1.5167 EBITDA-156.627 Million
Price to Book Value0.0 Operating Margin-143.4117 Enterprise Value1.037 Billion
Current Ratio1.885 EPS Growth-1.201 Quick Ratio1.376
1 Yr BETA 0.1423 52-week High/Low 28.25 / 15.92 Profit Margin-161.9386
Operating Cash Flow Growth-49.5485 Free Cash Flow to Firm (FCFF) TTM -56.398 Million Free Cash Flow to Equity (FCFE) TTM-41.521 Million
Altman Z-Score-5.8489
View SEC Filings from XENT instead.

View recent insider trading info

Funds Holding XENT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XENT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-05-13:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 8.01: Other Events
  • 8-K: filed on 2022-04-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-23:
    Item 8.01: Other Events
  • 8-K: filed on 2021-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-08:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-09-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-27:
    Item 8.01: Other Events
  • 8-K: filed on 2021-08-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-08-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Proposed Sales (Form 144)

    Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MEAD DANA G JR.

    • Director
    0 2022-05-13 0

    MEIER RICHARD A EVP & CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-05-13 0

    BRODERICK PATRICK A EVP, GC & CORPORATE SECRETARY

    • Officer
    0 2022-05-13 0

    GALLAHUE KIERAN

    • Director
    0 2022-05-13 0

    LUCCHESE CYNTHIA L

    • Director
    0 2022-05-13 0

    WEST THOMAS A. PRESIDENT AND CEO

    • Officer
    • Director
    0 2022-05-13 0

    SANDOVAL ELISABETH

    • Director
    0 2022-05-13 0

    KLINE TERESA L.

    • Director
    0 2022-05-13 0

    FERNANDEZ REYNA M CHIEF HUMAN RESOURCE OFFICER

    • Officer
    0 2022-05-13 0

    HATTANGADI NEIL A

    • Director
    0 2022-05-13 0

    KOWALSKI CHRISTINE R EVP & CHIEF OPERATING OFFICER

    • Officer
    41,042 2021-02-04 0

    MOLL FREDERIC H

    • Director
    260,961 2021-01-19 0

    CARSCADDEN GWEN R. CHIEF PEOPLE OFFICER

    • Officer
    14,790 2021-01-04 0

    VERNON W ANTHONY

    • Director
    21,049 2020-06-04 0

    BINNEY ROBERT H JR CHIEF COMMERCIAL OFFICER

    • Officer
    37,555 2020-03-02 0

    LEHMAN DAVID AARON EVP & GENERAL COUNSEL

    • Officer
    100,475 2020-02-03 0

    EARNHARDT LISA D

    • Director
    884,386 2019-07-24 0

    STIMSON SUSAN P CHIEF STRATEGY OFFICER

    • Officer
    42,532 2019-06-13 0

    HILLEMAN JERYL L CHIEF FINANCIAL OFFICER

    • Officer
    43,836 2019-05-07 0

    KAUFMAN RICHARD E TECHNICAL ADVISOR

    • Officer
    85,280 2019-01-01 0

    PARKER DRAKE R. CHIEF BUSINESS OFFICER

    • Officer
    17,000 2018-01-17 0

    TANSEY CASEY M

    • Director
    8,581 2017-06-01 0

    WOLBECK AMY V.P. REGULATORY AFFAIRS & QLTY

    • Officer
    26,634 2016-09-06 0

    STAMBAUGH JAMES VP CLINICAL AFFAIRS

    • Officer
    20,000 2016-09-02 0

    MCKHANN CHAS CHIEF COMMERCIAL OFFICER

    • Officer
    55,000 2016-01-15 0

    DE CLERCQ CASPER L.

    • Director
    1,200,353 2015-05-12 0

    KLEINER PERKINS CAUFIELD & BYERS XI-A LP

    KLEINER PERKINS CAUFIELD & BYERS XI B LP

    KPCB XI ASSOCIATES, LLC

    • 10% Owner
    No longer subject to file 2015-05-11 0

    PRESIDIO MANAGEMENT GROUP IX, L.L.C.

    U S VENTURE PARTNERS IX L P

    FEDERMAN IRWIN

    KRAUSZ STEVEN M

    LIDDLE DAVID E

    MATTEUCCI PAUL A

    ROOT JONATHAN D

    YOUNG PHILIP M

    • 10% Owner
    No longer subject to file 2015-05-08 0

    PTV SCIENCES II L P

    PINTO TECHNOLOGY VENTURES GP II, L.P.

    PINTO TV GP CO LLC

    CRAWFORD MATTHEW S

    • 10% Owner
    No longer subject to file 2015-01-19 0

    ANDERSON RICK D

    • 10% Owner
    No longer subject to file 2015-01-19 0

    NORWEST VENTURE PARTNERS XI, LP

    NORWEST VENTURE PARTNERS XII, LP

    HAQUE PROMOD

    HOWARD MATTHEW D.

    CROWE JEFFREY

    • 10% Owner
    No longer subject to file 2014-07-29 0

    PTV SCIENCES II L P

    PINTO TECHNOLOGY VENTURES GP II, L.P.

    PINTO TV GP CO LLC

    • 10% Owner
    2,576,966 2014-07-29 0

    FLETCHER MARK J

    • Director
    0 2014-07-29 0

    PTV SCIENCES II L P

    PINTO TECHNOLOGY VENTURES GP II, L.P.

    PINTO TV GP CO LLC

    CRAWFORD MATTHEW S

    ANDERSON RICK D

    • 10% Owner
    0 2014-07-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INTERSECT ENT INC XENT 2022-05-13 22:15:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 21:45:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 21:15:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 20:45:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 20:15:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 19:45:04 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 19:15:03 UTC 0.4081 0.4119 650000
    INTERSECT ENT INC XENT 2022-05-13 18:45:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 18:15:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 17:45:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 17:15:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 16:45:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 16:15:03 UTC 0.408 0.412 650000
    INTERSECT ENT INC XENT 2022-05-13 15:45:03 UTC 0.408 0.412 450000
    INTERSECT ENT INC XENT 2022-05-13 15:15:03 UTC 0.408 0.412 450000
    INTERSECT ENT INC XENT 2022-05-13 14:45:03 UTC 0.4119 0.4081 450000
    INTERSECT ENT INC XENT 2022-05-13 14:15:03 UTC 0.4119 0.4081 450000
    INTERSECT ENT INC XENT 2022-05-13 13:45:03 UTC 0.4119 0.4081 450000
    INTERSECT ENT INC XENT 2022-05-13 13:15:03 UTC 0.4119 0.4081 450000
    INTERSECT ENT INC XENT 2022-05-13 12:45:03 UTC 0.4119 0.4081 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund XENT -262.0 shares, $-3104.7 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund XENT -26.0 shares, $-308.1 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund XENT -195.0 shares, $-2310.75 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments